What is the share price of ZIM Laboratories Ltd (ZIMLAB) today?
The share price of ZIMLAB as on 16th September 2026 is ₹136.78. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on ZIM Laboratories Ltd (ZIMLAB) share?
The past returns of ZIM Laboratories Ltd (ZIMLAB) share are- Past 1 week: 6.58%
- Past 1 month: 26.06%
- Past 3 months: 23.53%
- Past 6 months: 114.49%
- Past 1 year: 82.08%
- Past 3 years: 16.54%
- Past 5 years: 22.54%
What are the peers or stocks similar to ZIM Laboratories Ltd (ZIMLAB)?
The peers or stocks similar to ZIM Laboratories Ltd (ZIMLAB) include:What is the market cap of ZIM Laboratories Ltd (ZIMLAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of ZIM Laboratories Ltd (ZIMLAB) is ₹716.93 Cr as of 16th September 2026.What is the 52 week high and low of ZIM Laboratories Ltd (ZIMLAB) share?
The 52-week high of ZIM Laboratories Ltd (ZIMLAB) is ₹144.49 and the 52-week low is ₹59.31.What is the PE and PB ratio of ZIM Laboratories Ltd (ZIMLAB) stock?
The P/E (price-to-earnings) ratio of ZIM Laboratories Ltd (ZIMLAB) is 122.97. The P/B (price-to-book) ratio is 2.42.Which sector does ZIM Laboratories Ltd (ZIMLAB) belong to?
ZIM Laboratories Ltd (ZIMLAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy ZIM Laboratories Ltd (ZIMLAB) shares?
You can directly buy ZIM Laboratories Ltd (ZIMLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
ZIM Laboratories Ltd
ZIMLAB Share Price
NSE₹136.782.37% (+3.17)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ZIMLAB Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ZIMLAB Performance & Key Metrics
ZIMLAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 193.24 | 2.42 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.29 | 5.81 | 0.49% |
ZIMLAB Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
ZIMLAB Company Profile
ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments.
SUNPHARMA
PE Ratio
38.35
38.35
1Y Return
15.08%
15.08%
Buy Reco %
93.55
93.55
TORNTPHARM
PE Ratio
85.27
85.27
1Y Return
36.60%
36.60%
Buy Reco %
81.48
81.48
ZYDUSLIFE
PE Ratio
21.75
21.75
1Y Return
6.59%
6.59%
Buy Reco %
57.69
57.69
CIPLA
PE Ratio
28.13
28.13
1Y Return
12.89%
12.89%
Buy Reco %
62.86
62.86
LAURUSLABS
PE Ratio
117.14
117.14
1Y Return
112.52%
112.52%
Buy Reco %
58.33
58.33
ZIMLAB Sentiment Analysis
ZIMLAB Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ZIMLAB Stock Summary · August 2026
Management framed the quarter as one of its better first quarters in recent years, with operating momentum improving even as profitability stayed subdued. Total operating income rose 31.2% year over year to about INR 942 million in Q1 FY27, but EBITDA margin was only 3.7% and PAT remained a loss of INR 40 million, reflecting a heavier cost base and weaker absorption of fixed expenses. Exports continued to anchor the business, contributing about 84% of income, while the new innovative product portfolio and oral insulin business accounted for about 18% of revenue, underscoring the shift toward higher-value products. Management emphasized that the EU-GMP reinspection has been completed, the draft report contained no adverse or critical observations, and the final report is expected imminently, which should unlock regulated-market supplies after an estimated two-quarter lag. They also noted that one-time audit, maintenance, and MIDC costs should not recur next quarter, and said margins should improve as revenue scales, with full-year FY28 growth and margin expansion tied largely to the EU approval-driven ramp.
ZIMLAB Stock Growth Drivers
ZIMLAB Stock Growth Drivers
9EU-GMP Remediation Nears Completion
Management said the EU-GMP reinspection has been completed and the business is now awaiting the
Core Business Momentum and Revenue Growth
The company reported healthy revenue growth in the quarter, supported by continued strength in the
ZIMLAB Stock Challenges
ZIMLAB Stock Challenges
5EU-GMP remediation and approval dependency
The company remains heavily dependent on resolving EU-GMP remediation before a major part of its
Margin pressure from elevated costs and weak operating leverage
Near-term profitability is being constrained by a higher expense base, including employee costs, utilities, fuel
ZIMLAB Forecast
ZIMLAB Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
ZIMLAB
ZIMLAB
Income
Balance Sheet
Cash Flow
Quarterly Normal View
ZIMLAB Income Statement
ZIMLAB Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 119.40 | 82.82 | 93.46 | 98.08 | 110.44 | 73.23 | 90.75 | 110.36 | 111.44 | 95.17 | ||||||||||
Operating & Other expenses | 102.22 | 73.79 | 82.61 | 84.77 | 94.14 | 67.50 | 82.96 | 95.85 | 98.08 | 91.73 | ||||||||||
EBITDA | 17.18 | 9.03 | 10.85 | 13.31 | 16.30 | 5.73 | 7.79 | 14.51 | 13.36 | 3.44 | ||||||||||
| Depreciation/Amortization | 3.91 | 4.94 | 5.00 | 4.88 | 5.29 | 4.86 | 4.98 | 5.03 | 5.10 | 5.37 | ||||||||||
| PBIT | 13.27 | 4.09 | 5.85 | 8.43 | 11.01 | 0.87 | 2.81 | 9.48 | 8.26 | -1.93 | ||||||||||
| Interest & Other Items | 2.28 | 2.86 | 2.89 | 2.73 | 2.91 | 3.30 | 3.16 | 3.43 | 3.31 | 3.64 | ||||||||||
| PBT | 10.99 | 1.23 | 2.96 | 5.70 | 8.10 | -2.43 | -0.35 | 6.05 | 4.95 | -5.57 | ||||||||||
| Taxes & Other Items | 2.91 | 0.34 | 0.58 | 1.71 | 3.22 | -0.55 | 0.08 | 1.65 | 1.20 | -1.56 | ||||||||||
| Net Income | 8.08 | 0.89 | 2.38 | 3.99 | 4.88 | -1.88 | -0.43 | 4.40 | 3.75 | -4.01 | ||||||||||
| EPS | 1.66 | 0.18 | 0.49 | 0.82 | 1.01 | -0.38 | -0.09 | 0.90 | 0.76 | -0.75 |
ZIMLAB Company Updates
ZIMLAB Stock Peers
ZIMLAB Past Performance & Peer Comparison
ZIMLAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| ZIM Laboratories Ltd | 122.97 | 2.42 | — |
| Sun Pharmaceutical Industries Ltd | 38.35 | 5.25 | 0.87% |
| Torrent Pharmaceuticals Ltd | 85.27 | 10.49 | 0.70% |
| Zydus Lifesciences Ltd | 21.75 | 3.71 | 0.09% |
ZIMLAB Stock Price Comparison
Compare ZIMLAB with any stock or ETFCompare ZIMLAB with any stock or ETF
ZIMLAB
ZIMLAB Holdings
ZIMLAB Shareholdings
ZIMLAB Promoter Holdings Trend
ZIMLAB Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 2.90%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ZIMLAB Institutional Holdings Trend
ZIMLAB Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 2.25%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ZIMLAB Shareholding Pattern
ZIMLAB Shareholding Pattern
ZIMLAB Shareholding History
ZIMLAB Shareholding History
Foreign Institutions
Mutual Funds Invested in ZIMLAB
Mutual Funds Invested in ZIMLAB
No mutual funds holding trends are available
Top 1 Mutual Funds holding ZIM Laboratories Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0802% | Percentage of the fund’s portfolio invested in the stock 0.49% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 40/47 (-7) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ZIMLAB stock
smallcases containing ZIMLAB stock
Looks like this stock is not in any smallcase yet.
ZIMLAB Events
ZIMLAB Events
ZIMLAB Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ZIMLAB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ZIMLAB Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ZIMLAB has not given any dividends in last 5 years
ZIMLAB Upcoming Dividends
ZIMLAB Upcoming Dividends
No upcoming dividends are available
ZIMLAB Past Dividends
ZIMLAB Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2019
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 19, 2019
Cash Dividend
Ex DateEx DateSep 3, 2018
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 3, 2018
ZIMLAB Stock News & Opinions
ZIMLAB Stock News & Opinions
Articles & Videos
Corporate
Corporate
ZIM Laboratories FZE invested AED 916,000 in its subsidiary, ZIM Scientific Office LLCZIM Laboratories Limited announced that its wholly-owned subsidiary, ZIM Laboratories Limited FZE, has completed an investment of AED 4,66,000 and AED 4,50,000 in ZIM Scientific Office LLC, a step-down subsidiary, as previously disclosed on March 28, 2025, and August 7, 2025, maintaining ZIM FZE’s 100% shareholding in ZIM SO.
23 hours agoCapital Market - Live
Earnings
Earnings
Zim Laboratories Ltd consolidated sales down 10.53% on year in Q2FY2026, net profit tumbled by 207.49%Zim Laboratories Ltd share price inched up 4.47% to Rs 114.55. The Company's net profit witnessed a sharp fall of 207.49% to Rs 4.02 crore, while revenue from operations slipped 10.53% to Rs 94.18 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.84 lakh crore, gaining 5.02%. It has improved by 1.03% over last one week and rose by 11.63% in last one month while the market capitalization of Zim Laboratories Ltd has slipped by 0.39% and 11.44% in the same period respectively. Profit before tax (PBT) of Zim Laboratories Ltd stood at Rs 5.57 crore in Q2 FY26, jumping 129.22% year-on-year, and crashing by 212.75% quarter-on-quarter. EBITDA came in at Rs 1 crore, nosediving by 47.48% YoY and surging by 41.75% sequentially. Total expenses marginally dropped 5.89% to Rs 97.1 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 43.82 crore, falling by 11.83% YoY, while employee benefits expense was at Rs 19.18 crore, expanding by 10.29% YoY. For the TTM ended FY26, revenue from operations declined slightly by 1.22% to Rs 374.4 crore, while net profit plunged by 52.01% to Rs 5.84 crore, compared to previous TTM. EBITDA jumped by 3681% to Rs 18.63 crore, and PBT tanked by 54.41% to Rs 8.21 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 49.53 crore in FY26, as against Rs 41.15 crore in FY25. Zim Laboratories Ltd soared by 42.74% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.64% during the same period.
1 month agoCapital Market - Live
Corporate
Corporate
ZIM LABORATORIES LIMITED to review quarterly results at a board meeting on August 6, 2026ZIM LABORATORIES LIMITED will hold a board meeting on Thursday, August 6, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026, according to a filing with the BSE Limited and National Stock Exchange of India Limited. The trading window for the company's securities will be closed from Wednesday, July 1, 2026, to Saturday, August 8, 2026, in accordance with SEBI regulations and the company’s code of conduct.
1 month agoCapital Market - Live
Corporate
Corporate
Zim Laboratories AGM scheduledZim Laboratories announced that the Annual General Meeting(AGM) of the company will be held on 29 June 2026.
3 months agoCapital Market - Live
Corporate
Corporate
Zim Laboratories to hold board meetingZim Laboratories will hold a meeting of the Board of Directors of the Company on 19 May 2026.
4 months agoCapital Market - Live
Earnings
Earnings
Zim Laboratories consolidated net profit rises 10.00% in the December 2025 quarterNet profit of Zim Laboratories rose 10.00% to Rs 4.40 crore in the quarter ended December 2025 as against Rs 4.00 crore during the previous quarter ended December 2024. Sales rose 12.80% to Rs 108.66 crore in the quarter ended December 2025 as against Rs 96.33 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales108.6696.33 13 OPM %11.7912.01 - PBDT11.0810.58 5 PBT6.055.70 6 NP4.404.00 10 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Corporate
Zim Laboratories announces board meeting dateZim Laboratories will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Corporate
Zim Laboratories to conduct EGMZim Laboratories announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 16 February 2026.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Corporate
Zim Laboratories announces board meeting dateZim Laboratories will hold a meeting of the Board of Directors of the Company on 21 January 2026.Powered by Capital Market - Live
8 months agoCapital Market - Live
Spotlight
Spotlight
Zim Laboratories gets CDSCO nod for Naproxen'Esomeprazole combination capsuleThe formulation has been developed using the company's proprietary drug delivery technologies, combining naproxen delayed-release minitablets and esomeprazole pellets in a single hard gelatin capsule. Zim said the platform offers a differentiated, patient-friendly delivery system and forms part of its New Innovative Product (NIP) pipeline. The FDC is indicated for adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for reducing the risk of NSAID-associated gastric and duodenal ulcers. Zim Laboratories stated that the approval strengthens its presence in the pain-management and gastro-protective segments. The company has already signed a commercial supply agreement with an Indian pharmaceutical firm and is working toward launching the product in India in FY 2026'27 (FY27). Zim added that the approval aligns with its strategy of developing innovative, differentiated generics using advanced formulation technologies. ZIM Laboratories is a research-driven pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments. The company's consolidated net profit dropped 117.6% to Rs 0.42 crore as revenue fell 3.7% to Rs 88.71 crore in the quarter ended September 2025 as compared with the previous quarter ended September 2024. The scrip rose 0.45% to Rs 71.15 on the BSE. Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 4.5%, vs industry avg of 11.79%
Over the last 5 years, market share decreased from 0.11% to 0.08%
Over the last 5 years, net income has grown at a yearly rate of -4.45%, vs industry avg of 10.53%